


Hepatobiliary and Pancreas Disease-Oriented Team

Clinical Research Treatment Trial Flowchart





Open to Accrual
 Low Accruing
 Pending Activation/Suspended

SYSTEMIC + OPERATIVE

ETCTN 10608

Gemcitabine + Cisplatin +
Durva Neo/Adjuvant for **high-risk resectable ICC**

Coord: H. Nguyen
Accrual: 2/3

UCI 23-99

Randomize, adjuvant
Rilvegostomig/placebo +
capecitabine or gem/cisplatin
after BTC resection

Coord: H. Nguyen
Accrual: 0/8

FIRST LINE

UCI 22-211

MED1572 (IgG1 mAb) or
AZD2936 (TIGIT) ±
gemcitabine and cisplatin

**TBD more slots to be
released**

Coord: C. Kang
Accrual: 1/8

SECOND LINE+

ETCTN-10276

M3814 ± Avelumab +
Hypofraction Radiation

Coord: C. Kang
Accrual: 3/5

UCI 23-200

AZD0901 (CLND18 ADC)
Central prescreening

Coord: M. Duron
Accrual: 4/10



PERIOPERATIVE

BORDERLINE/ LOCALLY ADVANCED

ETCTN-10366

M3814 (Peposertib) + radiation
Coord: S. Duong
Accrual: 6/8

ETCTN-10464

Olaparib + Durvalumab + radiation

Coord: S. Duong
Accrual: 1/5

UCI 23-134

Padeliporfin Vascular targeted
photodynamic therapy

Pancreatic head/uncinate w/SMA

Coord: C. Kang
Accrual: 1/8

FIRST LINE LA/METASTATIC

UCI 23-200

AZD0901 (CLND18 ADC) with
NAL-IRI or Gemcitabine
Investigator discretion

Coord: S. Duong
Accrual: 4/10

UCI 22-51

ASP2138 (CLDN18.2 BiTe) with
FOLFIRINOX

Coord: P. Yang
Accrual: 22/25

UCI 24-82

IK-595 (MEK/RAF Inhibitor) with
Gemcitabine/nab-paclitaxel

KRAS mutations

Coord: C. Kang
Accrual: 7/10

SECOND LINE

ETCTN 10522

CA4948 + gemcitabine + nab-
paclitaxel

Coord: H. Nguyen
Accrual: 3/4

A022106

Nab-paclitaxel + Gemcitabine ±
Cisplatin
BRCA1/2 or PALB2
PD on 1L FOLFIRINOX

Coord: J. Balanguie
Accrual: 0/3

RECURRENT METASTATIC

UCI 24-08

SPEDOX -6 (Protein
encapsulated doxorubicin)
KRAS Mutation

Coord: J. Balanguie
Accrual: 0/50

**Review Biomarker Based
Solid Tumors Pages 6 and 7**



ADJUVANT

[S2104](#)
 Capecitabine + Temozolomide
 vs observation

Pancreatic NET Ki67 > 3%

Coord: J. Balangue
 Accrual: 0/2

SECOND LINE

[ETCTN 10479](#)
 Lu-177 + Sunitinib

Well or moderately
 differentiated PNET
 Up to one line of systemic
 therapy not including
 somatostatin

Coord: H. Nguyen
 Accrual: 0/3

SECOND LINE+

[ETCTN 10558](#)
 Lu-177 ± Triapine

NET w/positive 68 or 64
 DOTATATE on scans

Coord: H. Nguyen
 Accrual: 0/3

[UCI 23-75](#)

NET/NEC solid tumors with SST2
 expression

DOT approved

Mutation based studies allowing Pancreatic, HCC, and Biliary cancers + other solid tumors

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

HER2

TISSUE FACTOR

KRAS/NRAS

GERMLINE MUTATIONS

UCI 21-146
MRG004A (TF ADC)

Coord: M. Duron
Accrual: 5/11

UCI 21-53
LY3537982 (KRAS G12C Inhibitor)

Coord: J. Choe
Accrual: 7/12

ETCTN-10528
Novobiocin (POLθ)
Germline mutations

Coord: H. Nguyen
Accrual: 0/5

CLAUDIN 18.2

EpCAM

UCI 22-87
RMC-6236 (KRAS Inhibitor)

Pancreatic KRAS WT 2L

Coord: C. Kang
Accrual: 21/25

GERM/SOMATIC MUTATIONS

UCI 22-51
ASP2138 (CLDN18.2 BiTe)

Pancreatic and Gastric/GEJ

Coord: P. Yang
Accrual: 22/25

UCI 23-85
BA3182 (CAB T-cell: EpCAM)

All solid tumors (central EPCAM testing)

Coord: H. Nguyen
Accrual: 3/8

UCI 22-87
RMC-6236 (KRAS Inhibitor)

Pancreatic KRAS WT 2L

Coord: C. Kang
Accrual: 21/25

UCI 23-162
IMP1734 (PARP1)

PDAC Cohort 1A: BRCA1/2, PALB2, RAD51B/C/D

Coord: J. Balangue

UCI 24-82
NRAS, KRAS, BRAF mutations

Local testing; contact CRC for specific tumor types

Coord: C. Kang
Accrual: 7/10

Various solid tumors included, or have progressed on, exhausted all therapies, or not amenable to further treatment

UCI 22-26

CB-03-10 (Androgen and glucocorticoid antagonist)

All solid tumors

Coord: M. Duron

Accrual: 11/12

Open to Accrual
 Low Accruing
 Pending Activation/Suspended

BLOOD COLLECTION

UCI 21-124

ctDNA collection during HBP
workup

Coord: J. Balangué
Accrual: 16/17

UCI 23-10/PRECEDE

(Blood collection for early
detection of pancreatic
cancer)

Pending budget/contract